Immune cells engineered to attack deadly brain tumors in early trial
NCT ID NCT05168423
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 31 times
Summary
This early-phase study tests whether specially engineered immune cells (CART-EGFR-IL13Ra2) are safe and feasible for people with a recurrent, aggressive brain cancer called glioblastoma. About 67 adults whose tumors have returned after standard treatment will receive their own modified cells. The goal is to find the safest dose and see if the cells can target and attack the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.